However, previous implementations did not offer face-to-face consultation between the patient and pharmacist and were instead focused on specific therapeutic areas or medication classes (e.g., chronic pain and CYP2D6-metabolized opioids [e.g., codeine, tramadol, hydrocodone] or depression and certain selective serotonin reuptake inhibitors [SSRIs; all except fluoxetine]). Here, CYP2D6 is linked to depressive symptom measurement.